Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, announced that it has exercised its option to in-license the first nuclease drug development programme under its research collaboration and option agreement with Masaryk University in the Czech Republic.
The collaboration was formed in June 2017 to discover and develop novel cancer treatments by targeting DNA nucleases involved in the DDR.
Niall Martin, Chief Executive Officerat Artios Pharma, said: “We are delighted to announce the in-licensing of our first nuclease programme from Masaryk University. This reflects the strong progress that has been made under our research and development collaboration with Drs Krejci and Paruch at Masaryk University on DDR nucleases. The in-licensed programme has the potential to become a novel, first-in-class DDR targeted treatment for cancer, which complements our current development pipeline and further supports our position as a leader in the DDR field.”